243 related articles for article (PubMed ID: 36357822)
21. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
23. The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
Shawky H; Abo Hamar AH; Galal S; Zakaria F; El-Shorbagy D
J Egypt Natl Canc Inst; 2009 Jun; 21(2):107-19. PubMed ID: 21057562
[TBL] [Abstract][Full Text] [Related]
24. A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma.
Attarian F; Taghizadeh-Hesary F; Fanipakdel A; Javadinia SA; Porouhan P; PeyroShabany B; Fazilat-Panah D
Front Oncol; 2021; 11():779491. PubMed ID: 34900732
[TBL] [Abstract][Full Text] [Related]
25. Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study.
Chen J; Wang T; Liu W; Qiu H; Zhang N; Chen X; Ding X; Zhang L
Front Oncol; 2022; 12():1000501. PubMed ID: 36483042
[TBL] [Abstract][Full Text] [Related]
26. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
[TBL] [Abstract][Full Text] [Related]
27. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P
Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Guo C; Yang Q; Xu P; Deng M; Jiang T; Cai L; Li J; Sai K; Xi S; Ouyang H; Liu M; Li X; Li Z; Ni X; Cao X; Li C; Wu S; Du X; Su J; Xue X; Wang Y; Li G; Qin Z; Yang H; Zhou T; Liu J; Hu X; Wang J; Jiang X; Lin F; Zhang X; Ke C; Lv X; Lv Y; Hu W; Zeng J; Chen Z; Zhong S; Wang H; Chen Y; Zhang J; Li D; Mou Y; Chen Z
JAMA Netw Open; 2023 Jan; 6(1):e2253285. PubMed ID: 36705923
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Han SJ; Rolston JD; Molinaro AM; Clarke JL; Prados MD; Chang SM; Berger MS; DeSilva A; Butowski NA
Neuro Oncol; 2014 Sep; 16(9):1255-62. PubMed ID: 24670608
[TBL] [Abstract][Full Text] [Related]
30. Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial.
Mao Y; Yao Y; Zhang LW; Lu YC; Chen ZP; Zhang JM; Qi ST; You C; Wang RZ; Yang SY; Zhang X; Wang JS; Chen JX; Yang QY; Shen H; Li ZY; Wang X; Ma WB; Yang XJ; Zhen HN; Zhou LF
Chin Med J (Engl); 2015 Oct; 128(20):2751-8. PubMed ID: 26481741
[TBL] [Abstract][Full Text] [Related]
31. Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide.
Quan R; Zhang H; Li Z; Li X
Medicine (Baltimore); 2020 Jan; 99(2):e18591. PubMed ID: 31914038
[TBL] [Abstract][Full Text] [Related]
32. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
[TBL] [Abstract][Full Text] [Related]
33. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
34. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C
Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
[TBL] [Abstract][Full Text] [Related]
35. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Hata N; Mizoguchi M; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Amemiya T; Michiwaki Y; Fujioka Y; Takigawa K; Suzuki SO; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iihara K
J Neurooncol; 2020 Feb; 146(3):451-458. PubMed ID: 32020475
[TBL] [Abstract][Full Text] [Related]
36. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
[TBL] [Abstract][Full Text] [Related]
37. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
38. Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
Qiu X; Chen Y; Bao Z; Chen L; Jiang T
Radiother Oncol; 2022 Feb; 167():1-6. PubMed ID: 34902368
[TBL] [Abstract][Full Text] [Related]
39. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F
J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820
[TBL] [Abstract][Full Text] [Related]
40. Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.
Saito K; Mukasa A; Narita Y; Tabei Y; Shinoura N; Shibui S; Saito N
Neurol Med Chir (Tokyo); 2014; 54(4):272-9. PubMed ID: 24257502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]